Please login to the form below

Not currently logged in

FDA clears Warner Chilcott osteoporosis drug

Warner Chilcott has won US Food and Drug Administration approval for a new version of its postmenopausal osteoporosis drug Actonel

The Irish pharmaceutical firm Warner Chilcott has won US Food and Drug Administration (FDA) approval for a new version of its Actonel (risedronate sodium) drug, which is a once-weekly treatment for postmenopausal osteoporosis.

The new product will be marketed under the brandname Atelvia and is expected to be launched in early 2011. Unlike Actonel and other drugs in the same class, including Merck's Fosamax (alendronate), Atelvia does not have fasting requirements associated with dosing.

"We believe the dosing convenience of Atelvia sets it apart from other treatment options for osteoporosis patients and provides an opportunity to regain market share in the US in this segment," Roger Boissonneault, president and CEO of Warner Chilcott, said in a statement.

In addition, Atelvia gives Warner Chilcott a new lease on its patent protection for the osteoporosis drug. The patent on the old formulation, which has been a major profit driver for the company, expires in 2014, but Atelvia is patent-protected in the US until 2026.

14th October 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...